Shares of development-stage biopharma ArQule (NASDAQ: ARQL) rose nearly 17% today after the company announced two appointments to its management team in two newly created positions. Dr. Marc Schegerin will serve as senior vice president, corporate strategy, communication, and finance. Dr. Shirish Hirani will serve as senior vice president, program management and product planning. It's a fairly standard move, but investors are taking it as a sign of maturation for the tiny biopharma company focused on developing treatments for cancer and rare diseases.